Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based…

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 18,668 followers.

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170) https://t.co/gT5yGh5bS6

15 Nov 2023

Reply Repost Favourite

RT @FrontOncology: New research: Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-st…

27 Oct 2023

Reply Repost Favourite

New research: Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170): Introduction … https://t.

26 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.